Targeting mTOR dependency in pancreatic cancer by Morran, Douglas C. et al.
  
 
 
Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic 
cancer. Gut, 63 (9). pp. 1481-1489. ISSN 0017-5749 
 
Copyright © 2014 The Authors 
 
 
 
http://eprints.gla.ac.uk/97235/ 
 
 
 
 
Deposited on: 29 September 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
ORIGINAL ARTICLE
Targeting mTOR dependency in pancreatic cancer
Douglas C Morran,1 Jianmin Wu,2 Nigel B Jamieson,3 Agata Mrowinska,1
Gabriela Kalna,1 Saadia A Karim,1 Amy Y M Au,1 Christopher J Scarlett,4
David K Chang,2,3,5,6,7 Malgorzata Z Pajak,1 Australian Pancreatic Cancer
Genome Initiative (APGI), Karin A Oien,1,8 Colin J McKay,3 C Ross Carter,3
Gerry Gillen,9 Sue Champion,10 Sally L Pimlott,10 Kurt I Anderson,1
T R Jeffry Evans,1,8 Sean M Grimmond,7,11 Andrew V Biankin,2,3,5,6,7
Owen J Sansom,1 Jennifer P Morton1
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
gutjnl-2013-306202).
For numbered afﬁliations see
end of article.
Correspondence to
Dr Jennifer P Morton,
Cancer Research UK Beatson
Institute, Garscube Estate,
Switchback Rd, Glasgow G61
1BD, UK;
j.morton@beatson.gla.ac.uk
Received 4 October 2013
Revised 4 March 2014
Accepted 21 March 2014
Published Online First
9 April 2014
▸ http://dx.doi.org/10.1136/
gutjnl-2014-307317
To cite: Morran DC, Wu J,
Jamieson NB, et al. Gut
2014;63:1481–1489.
ABSTRACT
Objective Pancreatic cancer is a leading cause of
cancer-related death in the Western world. Current
chemotherapy regimens have modest survival beneﬁt.
Thus, novel, effective therapies are required for treatment
of this disease.
Design Activating KRAS mutation almost always drives
pancreatic tumour initiation, however, deregulation of
other potentially druggable pathways promotes tumour
progression. PTEN loss leads to acceleration of KrasG12D-
driven pancreatic ductal adenocarcinoma (PDAC) in mice
and these tumours have high levels of mammalian target
of rapamycin (mTOR) signalling. To test whether these
KRAS PTEN pancreatic tumours show mTOR
dependence, we compared response to mTOR inhibition
in this model, to the response in another established
model of pancreatic cancer, KRAS P53. We also
assessed whether there was a subset of pancreatic
cancer patients who may respond to mTOR inhibition.
Results We found that tumours in KRAS PTEN mice
exhibit a remarkable dependence on mTOR signalling. In
these tumours, mTOR inhibition leads to proliferative
arrest and even tumour regression. Further, we could
measure response using clinically applicable positron
emission tomography imaging. Importantly, pancreatic
tumours driven by activated KRAS and mutant p53 did
not respond to treatment. In human tumours,
approximately 20% of cases demonstrated low PTEN
expression and a gene expression signature that overlaps
with murine KRAS PTEN tumours.
Conclusions KRAS PTEN tumours are uniquely
responsive to mTOR inhibition. Targeted anti-mTOR
therapies may offer clinical beneﬁt in subsets of human
PDAC selected based on genotype, that are dependent
on mTOR signalling. Thus, the genetic signatures of
human tumours could be used to direct pancreatic
cancer treatment in the future.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the
fourth commonest cause of cancer death in the UK
and has an estimated global incidence of 279 000 per
annum.1 There has been minimal improvement in
survival for over 30 years, and 80–90% of cases
present with either locally advanced or metastatic
disease, which precludes curative surgery. The major-
ity of patients who do undergo resection inevitably
develop recurrent or metastatic disease. Additionally,
most systemic therapies are largely ineffective.
Gemcitabine monotherapy has modest clinical
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Signiﬁcance of this study
What is already known on this subject?
▸ Pancreatic cancer is one of the leading causes
of cancer death. Most therapies are largely
ineffective and new therapies are required.
▸ Pancreatic cancer is nearly always driven by
KRAS mutation, with progression driven by
mutations in other genes, notably CDKN2A,
TP53 and DPC4. The disease is very complex
genetically, however, and many more genes are
mutated at low frequencies.
▸ There may be pathways that, although deregulated
relatively rarely, are key to driving speciﬁc tumours.
What are the new ﬁndings?
▸ Mammalian target of rapamycin (mTOR)
inhibition can lead to proliferative arrest and
even tumour regression in pancreatic tumours
driven by activated KRAS and PTEN deﬁciency,
but not in tumours driven by activated KRAS
and mutant p53.
▸ Therapeutic response to mTOR inhibition can
be assessed using clinically applicable positron
emission tomography imaging.
▸ ∼20% human pancreatic tumours exhibit low
PTEN expression, and a gene expression signature
that overlaps with murine KRAS PTEN tumours.
How might it impact on clinical practice in
the foreseeable future?
▸ This study is important as it is the ﬁrst to show
efﬁcacy of a targeted therapy in a preclinical
model of pancreatic cancer using the
genotype-to-phenotype approach.
▸ Targeted anti-mTOR therapies may offer clinical
beneﬁt in subsets of human pancreatic ductal
adenocarcinoma, selected based on genotype
that are dependent on mTOR signalling.
▸ The genetic signatures of human tumours could
be used to direct personalised pancreatic
cancer treatment in the future.
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beneﬁt and a marginal survival advantage in patients with
advanced PDAC,2 however, the median survival of patients with
metastatic PDAC remains poor, and is often less than 6 months.2
More recently, encouraging results have been observed in clinical
trials with the FOLRIFINOX regimen,3 although many patients
are unable to tolerate this regimen. Consequently, novel, effective
therapies are required for advanced and early disease.
PDAC development follows a well-characterised progression
model from benign precursor lesions known as pancreatic epithe-
lial neoplasia (PanIN) to the highly aggressive resultant tumour.
In almost all cases, mutation of KRAS is the likely initiating
lesion. The subsequent acquisition of mutations in a number of
tumour suppressor genes, notably CDKN2A, TP53 and DPC4,
and many more at lower frequencies,4 leads to tumour progres-
sion and metastasis, in a process now believed to occur over a
period of 10–20 years.5 Recent sequencing studies of pancreatic
cancer have reinforced the complexity and heterogeneity of this
disease.4 Thus, although there may be pathways that are key to
driving speciﬁc tumours, they may be deregulated relatively
rarely. Targeting the consequent aberrant signalling pathways,
however, represents an attractive novel therapeutic approach in
patients selected on their molecular proﬁle.
This approach leads to challenges in recruiting adequate
numbers of such patients for clinical studies. Here, preclinical
mouse models provide the opportunity to identify key action-
able phenotypes and distinct sensitivities, and build conﬁdence
in observations in very low patient numbers. In fact, two reports
of exceptional responders to mammalian target of rapamycin
(mTOR) inhibition were recently published, ﬁrst, in a patient
with Peutz–Jeghers syndrome and advanced pancreatic cancer,6
and second, in a single patient in a trial of an AKT inhibitor
who was subsequently shown to have activating KRAS mutation
and loss of PTEN.7 These studies suggest that there may be a
therapeutic opportunity for inhibition of mTOR in selected
patients with pancreatic cancer.
Recent clinical interest in the inhibition of mTOR has been
renewed with the demonstration of antitumour activity in
patients with metastatic renal cell carcinoma.8 By contrast,
studies have failed to show antitumour efﬁcacy in patients with
pancreatic cancer.9 10 However, these phase II clinical trials
were performed in patients with gemcitabine-refractory disease,
and with no patient selection based on the molecular pathology
of the tumour. Pancreatic cancers are often described as hetero-
geneous and, while in excess of 90% will have activation of
KRAS,11 this is invariably accompanied by a wide variety of
tumour suppressor losses,12 which may contribute to the vari-
ability of clinical response to inhibition of speciﬁc pathways. We
recently found that approximately 15–20% of human PDAC
exhibit very high levels of active phosphorylated mTORS2448,
and these patients have signiﬁcantly reduced survival. Although
not typically mutated in pancreatic cancer, Pten was highly
mutated in two recent screens for gene mutations that accelerate
KrasG12D-driven pancreatic tumorigenesis.13 14 Additionally, we,
and others, developed a mouse model in which pancreas speciﬁc
deletion of one copy of PTEN, the negative regulator of mTOR,
rapidly accelerated KrasG12D-driven PDAC.15 16
In this study, we show that murine pancreatic tumours driven
by activated Kras and Pten deﬁciency are highly sensitive to
mTOR inhibition, by contrast with tumours driven by activated
Kras and mutation of Trp53, demonstrating that the therapeutic
‘phenotype’ is dependent on the genotype of tumours. Further,
we show that PTEN-deﬁcient tumours regress upon treatment,
and undergo a proliferative arrest that can be monitored using
positron emission tomography (PET) CT imaging, thus
providing a clinically relevant functional biomarker of thera-
peutic efﬁcacy. Genetically engineered mouse models, such as
these, are particularly useful to study PDAC and test novel ther-
apies, given that they closely recapitulate the human disease. In
the future, it is likely that they will become more widely used
preclinically to better model genotype-to-phenotype
approaches.
METHODS
Genetically modiﬁed mice
The Pdx1-Cre, LSL-KrasG12D, Ptenﬂ, and LSL-Trp53R172H mice
have been described previously.15 17 18 Mice on a mixed strain
background were kept in conventional animal facilities and experi-
ments carried out in compliance with UK Home Ofﬁce guidelines.
Mice were genotyped by Transnetyx (Cordova, Tennessee, USA).
Mice were treated with 10 mg/kg rapamycin or vehicle daily
by intraperitoneal injection, and/or 100 mg/kg gemcitabine
twice weekly by intraperitoneal injection. Animals were sacri-
ﬁced as per institutional guidelines, and tissues removed and
ﬁxed in 10% buffered formalin.
Ultrasound imaging
High-resolution ultrasound imaging was performed using the
Vevo770 System with a 35 MHz Real-Time Micro Visualisation
(RMV) scanhead (VisualSonics) as described previously.19
Tumours were measured from two dimensional images at the
maximal dimensions of the tumour. Anaesthesia was induced
and maintained throughout the procedure with a mixture of
isoﬂurane and medical air.
18F-30-Fluoro-30-deoxy-L-Thymidine PET-CT imaging
Pretreatment and post-treatment with rapamycin, mice were
anesthetised and given an intravenous bolus of 18F-30-
Fluoro-30-deoxy-L-Thymidine (18F-FLT, ∼6 MBq). After an uptake
phase of 2 h, PET-CT images were acquired using an Albira
scanner (Bruker, Billerica, Massachusetts, USA). Further details are
provided in the online supplementary material.
Immunohistochemistry
Immunohistochemical (IHC) analysis was performed on formalin-
ﬁxed parafﬁn-embedded sections according to standard protocols.
Primary antibodies used were anti-Pten, 1:100, anti-pAktS473
(1:50), anti-pmTORS2448 (1:100), anti-pS6 (1:400), anti-4EBP1
(1:500) (all Cell Signalling Technology), anti-Ki67 (1:200),
anti-p53 (1:200), anti-CD3 (1:75) (all Vector), anticleaved caspase
3 (1:800, R&D) and anti-CD31 (1:100, Abcam).
Tumour cell lines
Isolation of mouse PDAC cell lines from KC PTEN and KPC has
been previously described.15 17 Cell lines were cultured in
Dulbecco’s modiﬁed Eagle’s medium (Invitrogen) supplemented
with 10% FBS, 2 mM L-glutamine (Invitrogen) and penicillin/
streptomycin (50 units/mL) (Invitrogen), in a humidiﬁed incubator
at 37°C.
Immunoblotting
Western immunoblotting was performed according to standard
protocols. Primary antibodies used were against S6, pS6S235/236,
Akt, pAktS473, mTOR, pmTORS2448 (all 1:1000, Cell Signalling
Technology), and β-actin (1:5000, Sigma–Aldrich).
Tissue microarray analysis
The Glasgow human pancreatico-biliary tissue microarray has
been described previously.20 PTEN expression levels were
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scored based on staining intensity and area of tumour using a
weighted histoscore: Σ(1×%weak)+(2×%moderate)+(3×%
strong). Kaplan–Meier survival analysis with Log-Rank statistical
test was used to analyse overall survival from time of surgery. All
statistical analyses were performed using SPSS V.19 (Chicago,
Illinois, USA).
Gene expression analysis and signature generation
RNAwas isolated from mouse tumours using the RNeasy mini kit
(Qiagen). At least three mice of each genotype were arrayed on
Affymetrix microarrays (Paterson Institute Microarray Service).
The affymetrix cell intensity (cel) ﬁles were normalised with
Robust Multiarray Analysis in Partek Genomics Suite Software.
Anova was used to identify signiﬁcantly regulated genes and linear
contrasts calculated between all pairs of experimental groups.
Multiple test correction was performed for all calculated p values
employing Benjamini and Hochberg’s step-up method. Further
details are provided in the online supplementary material.
RESULTS
mTOR inhibition improves survival in a mouse model of
PTEN-deﬁcient PDAC
Genetically engineered mouse models (GEMMs) of PDAC recap-
itulate human pancreatic cancer in a number of ways, including
in their resistance to standard therapies.19 Thus, we used
GEMMs to assess whether tumours with activation of the mTOR
pathway would be exquisitely sensitive to mTOR inhibition. The
foundation for these models was the Pdx1-Cre; KrasG12D/+ (KC)
mouse model, in which expression of activated Kras is targeted
to the mouse pancreas using a conditional LSL-KrasG12D allele
activated by Cre-mediated recombination, with Cre under the
control of the pancreatic and duodenal homeobox1 promoter
(Pdx1). These KC mice develop PanINs throughout their pan-
creas, which appear largely senescent,17 but progress to develop
invasive PDAC at low frequency and with prolonged latency.21
When KC mice are crossed with animals bearing a Pten allele
ﬂanked by loxP sites, to generate Pdx1-Cre; KrasG12D/+; Ptenﬂox/+
(KC PTEN) mice, tumorigenesis is rapidly accelerated.15
As we wanted to determine whether mTOR inhibition with
rapamycin could arrest tumour growth in mice with late-stage
disease, we compared treatment of KC PTENmice, with treatment
in Pdx1-Cre; KrasG12D/+; Trp53R172H/+ (KPC) mice,18 which are
resistant to most therapies.19 Cohorts of KC PTEN and KPC mice
were established, and animals monitored until they developed clin-
ically detectable pancreatic tumours, at which point mice would
normally be sacriﬁced within 1–3 days. Clinical features displayed
by these mice include abdominal distension with a palpable mass,
weight loss and reduced mobility. At this stage, mice were exam-
ined by ultrasound imaging to conﬁrm the presence of pancreatic
tumour, and to assess tumour size. Mice were treated with rapamy-
cin, vehicle control, gemcitabine, or rapamycin in combination
with gemcitabine, monitored daily for clinical signs, and eutha-
nased when symptoms worsened.
In KC PTEN mice, rapamycin treatment either alone, or in
combination with gemcitabine (median survival, 56 days and
32 days, respectively) resulted in signiﬁcant clinical improve-
ment and a clear survival advantage compared with vehicle-
treated controls or gemcitabine monotherapy (median survival,
10 days and 14 days, respectively) (ﬁgure 1A). Gemcitabine
monotherapy had negligible beneﬁt, in line with recent
studies,19 22 23 and the increased survival in response to rapamy-
cin therapy was not improved by combination with gemcitabine
(ﬁgure 1A). Importantly, by contrast with the signiﬁcant survival
beneﬁt observed in KC PTEN mice, rapamycin treatment
offered little clinical beneﬁt in KPC mice (ﬁgure 1B), and the
improvement in survival was negligible compared with vehicle-
treated controls (median survival, 7days vs 2 days). Thus, treat-
ment with rapamycin is only effective in PTEN deﬁcient
tumours, suggesting that tumours with deregulated mTOR sig-
nalling may be uniquely sensitive to mTOR inhibition.
mTOR inhibition can induce tumour shrinkage in
Pten-deﬁcient PDAC
In order to conﬁrm presence of tumour in symptomatic animals
prior to treatment, and to assess response, in terms of size, to
rapamycin or vehicle, we used in vivo ultrasound imaging.
Initial measurements of maximal tumour cross-sectional area
were on the ﬁrst day of treatment. When disease progressed,
animals were imaged again and a further cross-sectional meas-
urement taken of the tumour (ﬁgure 1C–E). We observed
tumour shrinkage in several of the KC PTEN mice following
rapamycin treatment (ﬁgure 1C,D), and even in those KC
PTEN tumours that did not regress, little progression was
observed even over several weeks of follow-up. By contrast, we
failed to achieve signiﬁcant responses in any KPC mice follow-
ing rapamycin treatment, and all KPC tumours showed a steady
increase in size, even over a brief time period, as symptoms
quickly worsened (ﬁgure 1C,E).
When the pancreata of mice were examined histologically, we
observed marked changes in rapamycin-treated KC PTEN mice
that became more pronounced with time on treatment. Solid
tumour tissue appeared to regress, causing the formation of
cysts within the pancreas (ﬁgure 2A). Importantly, neither
vehicle-treated tumours (ﬁgure 2A, left panels), nor rapamycin-
treated KPC tumours (ﬁgure 2A, lower panels,) were affected
histologically. The area of cystic morphology was signiﬁcantly
higher in rapamycin-treated KC PTEN tumours compared with
KPC tumours (ﬁgure 2B, p=0.030), and correlated with dur-
ation of treatment (ﬁgure 2B, Spearman’s r=0.596, p=0.019).
Our data suggest that mTOR inhibition may be effective in a
subset of human pancreatic tumours that are dependent on
mTOR signalling, and importantly, could offer clinical beneﬁt
even in patients with late-stage disease.
Rapamycin has been reported to have antiangiogenic
effects,24 so we performed IHC staining for the endothelial cell
marker CD31, to allow us to score vasculature in treated mice.
Importantly, we found that rapamycin treatment had no discern-
able effect on the vasculature in KC PTEN mice following treat-
ment, although there was a signiﬁcant reduction in vessel counts
in the KPC mouse model (p=0.050, ﬁgure 2C). Thus, rapamy-
cin does not exert its antitumoral effect through inhibiting
angiogenesis. Rapamycin also has immunosuppressive effects,
particularly targeting T cells,25 so we also examined the number
of CD3-positive T cells in the pancreata of our mice following
treatment. We were able to observe a marked reduction in the
number of CD3-positive T-cells in response to rapamycin treat-
ment, however, this was equivalent in the KC PTEN and KPC
mice (ﬁgure 2D). These data suggest that rapamycin is not
exerting its effect via suppression of T-cells, and our data thus
far implies a direct targeting of tumour cells.
mTOR inhibition abrogates proliferation in
Pten-deﬁcient PDAC
We were therefore interested in understanding how mTOR
inhibition affected tumours in KC PTEN mice at cellular level.
To test whether rapamycin could induce apoptosis of tumour
cells, we performed IHC for cleaved caspase 3. Tumours har-
vested from mice 3–4, 7–9 and >21 days post-treatment were
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assessed, and we found that there was no signiﬁcant induction
of apoptosis in response to rapamycin treatment in KC PTEN
mice (ﬁgure 2E). There was no signiﬁcant induction of apop-
tosis in KPC mice 3–4 days after treatment either, but in those
mice that survived 7–9 days post-treatment there was an increase
(p=0.050) in apoptotic cells, potentially due to the size of
tumours, and resulting hypoxia and necrosis by this time-point.
Given these ﬁndings, we hypothesised that the therapeutic
efﬁcacy of rapamycin in Pten-deﬁcient tumours is achieved
through growth arrest. We therefore assessed how rapamycin
affected tumour cell proliferation by IHC for the proliferation
marker Ki67. KC PTEN mice showed a marked reduction in the
numbers of Ki67-positive cells following rapamycin treatment
compared with control-treated mice (ﬁgure 3A, upper panels).
There was a dramatic inhibition of proliferation 3–4 days post-
treatment, and importantly, this inhibition continued with pro-
longed treatment and became signiﬁcantly more pronounced in
animals treated for more than 21 days (ﬁgure 3A upper panels,
and ﬁgure 3B, p=0.034). There was a similar reduction in the
number of Ki67-positive cells 3–4 days post-treatment in KPC
mice, however, this effect was not sustained, and tumours from
those animals that survived 7–9 days post-treatment showed the
number of Ki67-positive cells was restored to a level similar to
that seen in control animals (ﬁgure 3A lower panels, and
ﬁgure 3B, p=0.465). When we examined p53 expression in
rapamycin-treated KC PTEN mice we also found a signiﬁcant
increase in the number of p53-positive cells following treatment
(see online supplementary ﬁgure S2A, p=0.050), consistent
with this proliferative arrest. Since the lower proliferative index
we observed in rapamycin-treated KC PTEN tumours coincided
with histological change, we wanted to investigate whether
changes in differentiation were responsible for the decrease in
proliferation. We did not observe any changes in levels of
amylase or cytokeratin 19, or the mucins MUC1, MUC2 or
MUC5AC in rapamycin-treated KC PTEN tumours (see online
supplementary ﬁgure 1). Nevertheless, we cannot completely
rule out the possibility that the lower proliferative index is a
consequence of the cystic phenotype, rather than the cause.
Since our data indicated that rapamycin treatment results in pro-
liferative arrest, we wanted to measure this arrest in vivo, and also
assess a potential biomarker of therapeutic efﬁcacy. PET imaging
has been used clinically and preclinically to evaluate therapeutic
efﬁcacy. In fact, PET imaging may be able to detect metabolic or
proliferative changes earlier than the changes in tumour size that
are detected by other imaging modalities.26 Thus, we performed
PET imaging with 18FLT, a probe that marks cell proliferation,27
before and after rapamycin treatment in tumour-bearing KC
PTEN and KPC mice. We observed a clear PET signal from the
tumour in all mice imaged prior to treatment, conﬁrming that
these are highly proliferative tumours (ﬁgure 3C). Most exciting,
however, was our ﬁnding that following treatment with rapamycin
there was signiﬁcantly reduced uptake of tracer in the tumours of
all three KC PTEN mice (ﬁgure 3C,D). By contrast, we observed a
marked reduction in uptake in only one out of the three KPC mice
(ﬁgure 3D), and this one response may reﬂect the transient reduc-
tion in proliferation that we observed by IHC in KPC tumours, or
the possibility that the tumour may have acquired a mutation
affecting mTOR signalling. Consequently, we believe that 18FLT
Figure 1 Inhibition of mammalian target of rapamycin (mTOR) can delay tumorigenesis and improve survival even in late-stage PTEN-deﬁcient
pancreatic ductal adenocarcinoma (PDAC). (A) Kaplan–Meier survival curve showing that the survival of KC PTEN mice with symptomatic PDAC
treated daily with either 10 mg/kg intraperitoneal rapamycin as a single agent (n=18, red solid line), or in combination with twice weekly 100 mg/
kg intraperitoneal gemcitabine (n=9, red dashed line), was signiﬁcantly increased compared with either vehicle control treated mice (n=6, blue solid
line), or with gemcitabine treated mice (n=5, blue dashed line). (B) Kaplan–Meier survival curve showing that the survival of KPC mice with
symptomatic PDAC treated daily with 10 mg/kg intraperitoneal rapamycin (n=16, red line), was not signiﬁcantly increased compared with vehicle
control treated mice (n=8, blue solid line). (C) Chart showing the change in tumour volume between the start of rapamycin treatment and the time
of sacriﬁce (days of treatment on x-axis) in KC PTEN mice (blue bars) compared with KPC mice (red bars). (D) Ultrasound images of a pancreatic
tumour in a KC PTEN mouse prior to and post-treatment. (E) Ultrasound images of a pancreatic tumour in a KPC mouse prior to and post-treatment.
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uptake (or lack of) may represent a promising functional bio-
marker that could be further developed for use as an indicator of
antitumour efﬁcacy in future clinical trials.
mTOR inhibition with rapamycin acts primarily through S6
ribosomal protein
Although approved for some cancers, most clinical trials of rapalo-
gues have been disappointing. Although this is likely due to a lack
of patient selection, one reason frequently cited is that while rapa-
mycin is very effective in targeting S6 kinase, it is less effective at
targeting 4E-BP1.28 This was thought to be important as several
studies suggested that 4E-BP1 is required for mTOR-mediated cell
proliferation.29–31 Additionally, resistance to mTOR inhibition is
reported to occur through loss of 4E-BPs or overexpression of
eIF4E, suggesting that the 4E-BP1 response is critical.31 Further,
incomplete inhibition of mTORC1-mediated phosphorylation of
4E-BPs, can lead to the activation of Akt via the loss of a negative
feedback mechanism.32–34
Thus, we examined the phosphorylation of downstream effec-
tors of signalling through mTORC1: S6 ribosomal protein (as a
read-out of S6K activity), and 4E-BP1. We also assessed expres-
sion of the phosphorylated form of mTOR itself, and of AKT
(ﬁgure 4). As expected, tumours in KC PTEN exhibited very
high levels of phosphorylated mTOR compared with KPC mice
(ﬁgure 4, left inner panels and see online supplementary
ﬁgure S2B). Interestingly, phosphorylation of AKT was slightly
increased by treatment with rapamycin in tumours of either
genotype (ﬁgure 4, left outermost panels and see online supple-
mentary ﬁgure S2C), likely through loss of negative feedback on
IRS1 from S6K1 and resulting increased mTORC2 activity, as
has been described previously.32–34
Consistent with previously published work suggesting that
S6K is the principal downstream signal affected by rapamycin,
we observed decreased levels of pS6 in rapamycin-treated KC
PTEN mice, but not in treated KPC mice (ﬁgure 4, right inner
panels and see online supplementary ﬁgure S2D). By contrast,
the levels of p4E-BP1 were not signiﬁcantly altered by rapamycin
in either genotype (ﬁgure 4, right outermost panels and see
online supplementary ﬁgure S2E). Therefore, rapamycin appears
to be exerting its antitumour effects though S6K, and thus,
pS6 may be the best marker for measuring response to mTOR
inhibitors. These data were supported by experiments in cell
lines derived from KC PTEN and KPC tumours, in which rapa-
mycin treatment resulted in a dramatic inhibition of phosphoryl-
ation of S6 (see online supplementary ﬁgure S3). Interestingly,
rapamycin also blocked S6 phosphorylation in KPC cell lines,
even though treatment did not signiﬁcantly affect viability of
KPC cells in vitro, suggesting that Pten-deﬁcient cells are
uniquely dependent on mTOR signalling.
Low PTEN expression is associated with poor
survival in human PDAC
We ﬁnally wished to determine which patients might show sensi-
tivity to mTOR inhibition. Initially, we performed IHC for
Figure 2 Mammalian target of rapamycin (mTOR) inhibition can induce tumour regression in Pten-deﬁcient pancreatic ductal adenocarcinoma
(PDAC). (A) H&E-stained sections of PDAC harvested from mice treated with vehicle or 10 mg/kg rapamycin for 4, 9 or 30 days, as indicated. Cyst
formation is observed, and increases with time on treatment in KC PTEN mice (upper panels), but not in KPC mice (lower panels). (B) Boxplot
showing quantiﬁcation of cyst area as normalised to the total tumour area. (C) Boxplot showing quantiﬁcation of the number of CD31-positive
vessels per 400× ﬁeld of view in sections from rapamycin treated (red bars) or vehicle treated (blue bars) KC PTEN or KPC mice, as indicated. (D)
Boxplot showing quantiﬁcation of the number of CD3 positive cells per 400× ﬁeld of view in sections from rapamycin treated (red bars) or vehicle
treated (blue bars) KC PTEN or KPC mice, as indicated. (E) Graph showing quantiﬁcation of the number of cleaved caspase 3 positive cells per 400×
ﬁeld of view in sections from rapamycin, or vehicle treated KC PTEN or KPC mice, as indicated (blue=vehicle, red=3–4 days rapamycin, green=7–
9 days rapamycin, orange=>21 days rapamycin). 10 ﬁelds were assessed per mouse and at least three mice for each treatment group.
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PTEN on a tissue microarray of resected human pancreatic
tumour specimens. Expression was quantiﬁed using a histoscore
method, and patients were divided into groups of low (n=59,
mean histoscore 26.7) and high (n=58, mean histoscore 117.5)
expression. Low PTEN expression was associated with signiﬁ-
cantly poorer survival in these patients (ﬁgure 5A, p=0.017).
Furthermore, by multivariate analysis, low PTEN expression
was an independent predictor of survival (ﬁgure 5B). These data
were validated in a second group of patients in which low
PTEN expression was again associated with signiﬁcantly poorer
survival (ﬁgure 5C, p=0.026).
We also wanted to assess whether the gene expression signa-
ture of KC PTEN tumours might deﬁne a subset of human
PDAC. To identify a gene expression ‘signature’ speciﬁc to these
mice, principal component analysis (PCA) was used to compare
the transcriptome of these tumours with those arising in other
mouse models of pancreatic cancer, notably KPC,17 18
Pdx1-Cre, KrasG12D/+ Lkb1ﬂ/+20 and Pdx1-Cre, KrasG12D/+
Apcﬂ/+ mice (ﬁgure 5D). Importantly, the expression proﬁle of
the KC PTEN murine tumours was distinct from other tumours
(ﬁgure 5D). We identiﬁed a signature of 219 probes that deﬁned
the KC PTEN phenotype and could be further reﬁned to as few
as eight probes. These mouse probes were then mapped to
human microarray probes, and PCA analysis performed for each
signature across two cohorts of human tumour samples.
In both cohorts, we were able to identify three distinct clus-
ters of human pancreatic cancer using these signatures
(ﬁgure 5E,G). Even when the smallest signature was used to
cluster patients, this set of probes signiﬁcantly correlated with
poor survival in both cohorts (ﬁgure 5F,H). We also performed
IHC to quantify protein expression of PTEN on a subset of
tumours in the second cohort (n=46). These patients were used
in an enrichment analysis whereby Fisher’s exact test was used
to test whether any of these gene expression clusters were
enriched with a speciﬁc group of patients based on PTEN histo-
score. Patients with low PTEN expression (histoscore ≤80,
n=15) were more likely to be included in cluster 2 (red bars in
ﬁgure 5G, p=0.009), importantly, the cluster with poorest sur-
vival. Thus, gene expression analysis of patient tumours, using a
very small set of probes, may prove valuable as a method by
which to identify patients with deregulated mTOR signalling,
particularly where there is loss of function, but not of expres-
sion. Taken together, our data make a convincing case for the
use of mTOR inhibitors in carefully selected human pancreatic
cancer patients, and importantly, gene expression analysis might
allow us to identify those patients.
Figure 3 Mammalian target of rapamycin (mTOR) inhibition abrogates proliferation in Pten-deﬁcient pancreatic ductal adenocarcinoma (PDAC). (A)
Immunohistochemical staining for the proliferation marker Ki67 showing that rapamycin treatment results in a marked inhibition of proliferation in
KC PTEN mice (upper panels), but not in KPC mice (lower panels). Sections from tumours harvested at the indicated time-points are shown here. (B)
Graph showing quantiﬁcation of the number of Ki67 positive cells per 400× ﬁeld of view in sections from rapamycin or vehicle treated KC PTEN or
KPC mice, as indicated. Ten ﬁelds were assessed per mouse, and at least 3 mice for each treatment group (blue=vehicle, red=3–4 days rapamycin,
green=7–9 days rapamycin, orange=21+ days rapamycin). (C) Representative coronal plane 18F-30-Fluoro-30-deoxy-L-Thymidine (18FLT) positron
emission tomography (PET)-CT images show the PET signal emitted from the pancreatic tumour (white arrows) as well as excreted tracer in the
bladder (arrowheads) in a KC PTEN mouse at time of presentation (left panel), and after 4 days rapamycin treatment (right panel). (D) Graph of
18FLT uptake in KC PTEN and KPC tumours before, and following rapamycin treatment, based on maximum Standardised Uptake Value (SUVMax) in
region of interest, and normalised to liver (n=3).
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DISCUSSION
Clinical trials of mTOR inhibitors in advanced pancreatic
cancer have, thus far, have been preformed in unselected
patients. We previously found that there is a subgroup of up to
20% of human PDAC in which increased activation of AKT/
mTOR is associated with poor survival.14 And in sleeping
beauty screens using the Kras-driven pancreatic cancer model,
Pten ‘hits’ were the most common, reinforcing how important
deregulation of mTOR might be in driving PDAC.13 14 Here,
using a preclinical mouse model of PTEN-deﬁcient PDAC, we
have shown that survival can be signiﬁcantly extended using the
classical inhibitor of mTORC1, rapamycin, and this is associated
with a proliferative arrest. By contrast, there is little efﬁcacy of
rapamycin in the KPC model, typically used as a standard
model of treatment-resistant PDAC. We believe that our data
indicate that the KC PTEN model is exquisitely dependent
upon signalling via mTOR, whereas the KPC model is not.
These data demonstrate very well, preclinically at least, the
value of the genotype-to-phenotype approach of targeting
actionable phenotypes on the basis of genomic alterations.
Interestingly, a recent study found that activated PI3K signal-
ling could phenocopy mutant Kras in a mouse model of pancre-
atic cancer, and concluded that KRAS acts through PI3K
signalling to induce cancer.35 While the authors suggested that
therapeutic targeting of PI3K signalling might be a promising
approach for the treatment of pancreatic cancer, our data indicate
that response to treatment will be dependent on the combination
of genetic events in individual tumours. The antitumour effects
of rapamycin are mediated primarily through S6K inhibition in
our studies. The recent report that KRAS-induced pancreatic
cancer was substantially reduced in mice expressing an S6 mutant
that could not be phosphorylated also highlighted the import-
ance of this signalling arm downstream of mTOR.36 Inhibition of
mTOR, and thus S6 in our model led to proliferative arrest.
Others have found that the 4E-BP proteins mediate
mTOR-driven proliferation,29 37 however, we did not observe
any effects on 4E-BP1 phosphorylation following rapamycin
treatment. New research has shown that mTOR signals through
S6 to stimulate de novo pyrimidine synthesis, and thus, control
cell proliferation,38 39 and inhibition of this process may be the
mechanism by which proliferation is blocked in our mice.
This proliferative arrest may provide a useful biomarker of
therapeutic activity in clinical trials. Using a clinically relevant
imaging modality and tracer, we were able to visualise this pro-
liferative block days after commencing treatment, and it is not
unreasonable to think that this approach might be used in the
clinic. Pilot studies have already found that 18FLT and 18FDG
PET imaging can be used to predict therapeutic responses in
cancer patients,40 41 and this might be particularly important in
pancreatic cancer where repeat access to tissue can be limiting.
To date, human trials involving rapalogues have been per-
formed in patients with advanced disease, and with no selection
to identify tumours that might be particularly dependent upon
mTOR signalling. Our data suggest that, at least in resected cases,
only 20% of patients have aberrant activation of this pathway.
More germane, then, are the studies of exceptional responders:
Figure 4 Mammalian target of rapamycin (mTOR) inhibition with rapamycin acts primarily through S6K. (A–D) Immunohistochemical analysis of
pAKT, pmTOR, pS6 and 4EBP1 levels in vehicle and rapamycin treated KC PTEN and KPC tumours as indicated. Note the signiﬁcant reduction in
staining intensity of pS6 following rapamycin treatment in KC PTEN tumours, but not KPC tumours (highlighted in blue).
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most notably, a response to mTOR inhibition in a Peutz–Jeghers
patient,6 and also the trial of an AKT inhibitor in which a patient
with metastatic pancreatic cancer with known PTEN loss exhib-
ited a marked response.7 Both these reports nicely illustrate the
phenotype-to-genotype approach to targeted therapy.
Finally, our ﬁndings illustrate that targeted therapies are
effective with appropriate selection, and highlight the need for
more trials that test personalised therapies in patients where
there is a clear actionable phenotype. Preclinical models will be
extremely valuable for testing ﬁrst-line targeted therapies, and
also for determining mechanisms of resistance, and assessing
follow-up or combination treatments.
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